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Abstract
Background Metformin is a widely prescribed antidiabetic BCS Class III drug (low permeability) that depends on active 
transport for its absorption and disposition. It is recommended by the US Food and Drug Administration as a clinical sub-
strate of organic cation transporter 2/multidrug and toxin extrusion protein for drug–drug interaction studies. Cimetidine is 
a potent organic cation transporter 2/multidrug and toxin extrusion protein inhibitor.
Objective The objective of this study was to provide mechanistic whole-body physiologically based pharmacokinetic models 
of metformin and cimetidine, built and evaluated to describe the metformin-SLC22A2 808G>T drug–gene interaction, the 
cimetidine-metformin drug–drug interaction, and the impact of renal impairment on metformin exposure.
Methods Physiologically based pharmacokinetic models were developed in PK-Sim® (version 8.0). Thirty-nine clinical stud-
ies (dosing range 0.001–2550 mg), providing metformin plasma and urine data, positron emission tomography measurements 
of tissue concentrations, studies in organic cation transporter 2 polymorphic volunteers, drug–drug interaction studies with 
cimetidine, and data from patients in different stages of chronic kidney disease, were used to develop the metformin model. 
Twenty-seven clinical studies (dosing range 100–800 mg), reporting cimetidine plasma and urine concentrations, were used 
for the cimetidine model development.
Results The established physiologically based pharmacokinetic models adequately describe the available clinical data, 
including the investigated drug–gene interaction, drug–drug interaction, and drug–drug–gene interaction studies, as well as 
the metformin exposure during renal impairment. All modeled drug–drug interaction area under the curve and maximum 
concentration ratios are within 1.5-fold of the observed ratios. The clinical data of renally impaired patients shows the 
expected increase in metformin exposure with declining kidney function, but also indicates counter-regulatory mechanisms 
in severe renal disease; these mechanisms were implemented into the model based on findings in preclinical species.
Conclusions Whole-body physiologically based pharmacokinetic models of metformin and cimetidine were built and quali-
fied for the prediction of metformin pharmacokinetics during drug–gene interaction, drug–drug interaction, and different 
stages of renal disease. The model files will be freely available in the Open Systems Pharmacology model repository. Cur-
rent guidelines for metformin treatment of renally impaired patients should be reviewed to avoid overdosing in CKD3 and 
to allow metformin therapy of CKD4 patients.
1 Introduction
Metformin is an oral antidiabetic that reduces blood glu-
cose levels. It is the first-line therapy for type 2 diabetes 
mellitus (T2DM) and the fourth most commonly prescribed 
outpatient medication in the USA, with almost 80 million 
prescriptions in 2017 [1].
Metformin is a BCS Class III drug of high solubility and 
very low permeability, positively charged at physiologi-
cal pH and depends on active transport to cross biological 
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membranes. The metformin rate of absorption is slower than 
its rate of elimination [2] and the absorption is restricted 
to the upper intestine [3], leading to incomplete absorption 
of metformin, an oral bioavailability of 50–60%, and the 
excretion of approximately 30% of an oral dose, unabsorbed, 
with the feces [2, 4]. Furthermore, the absorption of met-
formin is saturable, with higher doses showing decreased 
dose-normalized plasma concentrations and a decreased 
fraction excreted to urine [4, 5]. Following its absorption, 
metformin is not bound to plasma proteins [2, 4, 6], not 
metabolized [2, 6], and not secreted to bile [2, 4, 7], but 
excreted unchanged with the urine by passive glomerular 
filtration and active renal secretion through the sequential 
action of organic cation transporter 2 (OCT2) and multidrug 
and toxin extrusion protein 1 (MATE1). Although there are 
early reports of MATE2-K expression in the human kid-
ney [8, 9], a recent quantitative study found only negligible 
amounts of MATE2-K compared to MATE1 [10]. Renal 
clearance is approximately 500 mL/min [11] with a strong 
correlation between the renal clearances of metformin and 
creatinine [4]. Patients with renal impairment show a marked 
increase in metformin exposure, with three- to ten-fold 
higher plasma trough concentrations in chronic kidney dis-
ease (CKD) stages 3A-5 [12]. As a consequence, metformin 
is contraindicated in patients with a glomerular filtration 
rate (GFR) < 30 mL/min (i.e., CKD stages 4 and 5) [13, 14], 
depriving these patients of metformin as a treatment option.
The impact of genetic polymorphisms on the absorp-
tion and disposition of metformin (drug–gene interactions 
or “DGIs”) has been investigated in a multitude of clini-
cal trials, yielding to some extent contradictory results. The 
transporters of primary interest in these studies were the 
plasma membrane monoamine transporter (PMAT), OCT1, 
OCT2, and MATE1, where variations in OCT2 seem to 
have the largest impact on the plasma concentrations of met-
formin [15–19]. The most common polymorphism in the 
gene encoding for OCT2 is the SLC22A2 808G>T single-
nucleotide polymorphism [20], which results in an amino 
acid exchange from alanine to serine (A270S) and presum-
ably increased function, leading to decreased exposure 
with ~ 13–20% decreased maximum concentration (Cmax) 
[17, 18, 21].
A third factor that impacts metformin exposure is 
drug–drug interactions (DDIs). Metformin displays a list 
of 333 DDIs, with 13 major and 293 moderate interactions 
[22]. Even though some of these occur on the pharmacody-
namic level, pharmacokinetic DDIs are clinically relevant 
and may call for an adjustment of the co-administration regi-
men. As metformin is exclusively eliminated by glomeru-
lar filtration and secretion through the renal organic cation 
transport system, co-treatment with a potent inhibitor of this 
transport pathway, such as cimetidine, decreases the renal 
clearance of metformin and increases metformin exposure 
(+ 50% area under the curve [AUC]) [21, 23]. Metformin is 
recommended by the US Food and Drug Administration as 
an OCT2/MATE victim drug for clinical DDI studies [24].
The aim of this study was to build and evaluate a whole-
body physiologically based pharmacokinetic (PBPK) model 
of metformin, applicable (1) to describe the impact of the 
metformin-SLC22A2 808G>T DGI on metformin exposure, 
(2) to dynamically model the cimetidine-metformin DDI, 
and (3) to analyze the impact of renal impairment on met-
formin exposure and generate dose recommendations for dif-
ferent stages of CKD. The newly developed and thoroughly 
evaluated metformin and cimetidine models will be freely 
available in the Open Systems Pharmacology PBPK model 
repository (https ://www.open-syste ms-pharm acolo gy.org), 
and the Electronic Supplementary Material (ESM) to this 
article is compiled to serve as a comprehensive and transpar-
ent documentation and reference.
Key Points 
A whole-body physiologically based pharmacokinetic 
model of metformin, the fourth most commonly pre-
scribed drug in the USA, has been carefully developed 
and evaluated to describe the metformin concentrations 
in blood, kidney, and urine. In addition, a whole-body 
physiologically based pharmacokinetic model of cime-
tidine, a potent multidrug and toxin extrusion protein 1 
inhibitor used in drug–drug interaction studies, has been 
established.
These models have been applied to describe and predict 
the metformin-SLC22A2 808G>T drug–gene interaction, 
the cimetidine-metformin drug–drug interaction, and a 
combined drug–drug–gene interaction study, in which 
different SLC22A2 genotypes were additionally chal-
lenged with cimetidine co-administration.
Furthermore, the pathophysiological changes during 
renal impairment have been assessed and implemented 
to describe the increased metformin exposure of patients 
with different stages of chronic kidney disease. For 
severe chronic kidney disease, this analysis indicates an 
induction of organic cation transporter 2 and multidrug 
and toxin extrusion protein 1, possibly as an adapta-
tion to progressing uremia/hyperuricemia. The final 
pathophysiologically based pharmacokinetic model was 
applied to generate metformin dosing recommendations 
for CKD3A-4 patients.
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2  Methods
2.1  Software
Physiologically based pharmacokinetic models were devel-
oped using PK-Sim® and  MoBi® modeling software (Open 
Systems Pharmacology Suite 8.0, https ://www.open-syste 
ms-pharm acolo gy.org). Published clinical study data were 
digitized with GetData Graph Digitizer 2.26.0.20 (© S. 
Fedorov). Model input parameter optimization (Leven-
berg–Marquardt algorithm, multiple starting values) and 
sensitivity analysis were performed in PK-Sim®. All phar-
macokinetic parameters and model performance measures 
derived from simulated and/or observed data were calculated 
in R 3.6.1 (The R Foundation for Statistical Computing, 
Vienna, Austria). Plots were generated in R and RStudio 
1.1.423 (RStudio, Inc., Boston, MA, USA).
2.2  Physiologically Based Pharmacokinetic Model 
Building
Physiologically based pharmacokinetic model building was 
started with an extensive literature search to collect physico-
chemical parameters, mechanistic information on absorp-
tion, distribution, metabolism, and excretion processes, as 
well as published clinical studies. The general procedure of 
PBPK model building, including parameter optimization and 
generation of virtual individuals and virtual populations, is 
described in the ESM.
2.3  Physiologically Based Pharmacokinetic Model 
Evaluation
Model performance was evaluated with multiple methods. 
First, predicted population plasma concentration–time pro-
files were compared with the data observed in the respec-
tive clinical studies. As the clinical data from literature is 
mostly reported as arithmetic means ± standard deviation, 
population prediction arithmetic means and 68% prediction 
intervals were plotted, which corresponds to the range of ± 1 
standard deviation around the mean, if normal distribution 
is assumed. In addition, the predicted plasma concentration 
values of all studies were plotted against their corresponding 
observed values in goodness-of-fit plots.
Furthermore, model performance was evaluated by com-
parison of predicted to observed AUC and Cmax values. All 
AUC values were calculated from the time of drug admin-
istration to the time of the last concentration measurement 
(AUC last).
As quantitative measures of model performance, mean 
relative deviation (MRD) of all predicted plasma concentra-
tions (Eq. 1) and geometric mean fold error (GMFE) of all 
predicted AUC last and Cmax values (Eq. 2) were calculated. 
MRD and GMFE values ≤ 2 characterize an adequate model 
performance.
where cpredicted,i is the predicted plasma concentration, 
cobserved,i is the corresponding observed plasma concentra-
tion, and k is the number of observed values.
where predicted PK  parameteri is the predicted AUC last 
or Cmax value, observed PK  parameteri is the correspond-
ing observed AUC last or Cmax value, and m is the number 
of studies.
Finally, the physiological plausibility of the param-
eter estimates and the results of sensitivity analyses were 
assessed. A detailed description of the sensitivity calculation 
is given in the ESM.
2.4  Modeling the Impact of Polymorphism
The impact of genetic polymorphism on the pharmacokinet-
ics of metformin was implemented by splitting the polymor-
phic transporter in question into two transporters with half 
of the initial reference concentration each, corresponding to 
the two homologous chromosomal alleles in diploid humans. 
Each “wild-type” allele present in the simulated population 
(one in heterozygous individuals and two in homozygous 
individuals) was modeled with the transport rate constant 
identified during the initial model development. Each “vari-
ant” allele was modeled with an adapted transport rate con-
stant that was identified based on clinical studies of met-
formin in homozygous “variant” individuals.
2.5  Drug–Drug Interaction Modeling
For mechanistic DDI modeling, the type of interaction (com-
petitive inhibition, mechanism-based inhibition, induction) 
and the interaction parameters were extracted from in-vitro 
literature. These parameters were incorporated into the per-
petrator PBPK model, to dynamically describe the impact of 
the perpetrator on the victim drug. The mathematical imple-
mentation is shown in the ESM.
The DDI modeling performance was assessed by com-
parison of predicted vs observed victim drug plasma con-
centration–time profiles when administered alone and during 
co-administration. In addition, predicted DDI AUC last ratios 
(Eq. 3) and DDI Cmax ratios (Eq. 4) were evaluated.
(1)




























1422 N. Hanke et al.
As a quantitative measure of the prediction accuracy, 
GMFE values of the predicted DDI AUC last ratios and DDI 
Cmax ratios were calculated according to Eq. (2).
2.6  Modeling of Renal Impairment
To model the impact of renal impairment on the pharma-
cokinetics of metformin, a literature search was conducted 
to identify the pathophysiological changes that occur in con-
junction with renal impairment, including their extent at the 
different stages of CKD. In a next step, these differences in 
anatomy and physiology were implemented to create renally 
impaired individuals and to describe the published clinical 
studies of metformin in patients with CKD.
3  Results
3.1  Metformin Physiologically Based 
Pharmacokinetic Model Building 
and Evaluation
A whole-body PBPK model of metformin has been suc-
cessfully developed. Thirty-nine clinical studies of intrave-
nous or oral administration covering a broad dosing range 
(0.001–2550 mg), 22 studies thereof with corresponding 
metformin fraction excreted to urine data, were utilized for 
PBPK model building and evaluation. In addition, human 
11C-metformin tissue concentration positron emission 
tomography (PET) measurements in the kidneys, liver, skel-
etal muscle, and intestines were included. Clinical studies 
are listed in the ESM.
To describe the pharmacokinetics of metformin, active 
transport processes by PMAT, OCT1, OCT2, and MATE1 
were implemented. These transporters were distributed and 
localized according to the current state of the literature, with 
their main sites of action illustrated in Fig. 1. PMAT was 
chosen to model the saturable absorption of metformin based 
on its good apparent affinity, high expression in the human 
small intestine, and localization at the luminal surface of 
enterocytes [25, 26], though the thiamine transporter 2 is 
also a likely candidate to contribute to the intestinal absorp-
tion of metformin [27, 28]. Renal excretion is modeled as 
passive glomerular filtration and active secretion through the 
sequential action of OCT2 and MATE1. Transporter distri-
bution, localization, and transport directions are summarized 
(3)
DDI AUClast ratio =
AUClast victim drug during co-administration
AUClast victim drug control
.
(4)
DDI Cmax ratio =
Cmax victim drug during co-administration
Cmax victim drug control
.
in the system-dependent parameter table in the ESM; trans-
port parameters are summarized in the metformin drug-
dependent parameter table in the ESM.
The good model performance is demonstrated in Fig. 2, 
using representative studies. Population predictions of all 39 
clinical studies compared to observed data, shown in semi-
logarithmic as well as linear plots, goodness-of-fit plots, and 
MRD values, are presented in the ESM. Predictions of met-
formin fraction excreted to urine are shown for all studies 
that provided observed data. For further evaluation of the 
model performance, predicted compared to observed AUC last 
and Cmax values, AUC last and Cmax GMFEs (1.20 and 1.24, 
respectively), and the results of the sensitivity analysis are 
documented in the ESM.
An important and novel feature of the presented model is 
the use of human 11C-metformin tissue concentration PET 
measurements for model development. As metformin is not 
metabolized, these PET images are unbiased by labeled 
metabolites. The unique transporter-controlled distribution 
of an intravenous 11C-metformin microdose over time [7] is 
shown in the upper part of Fig. 3. Noteworthy are the very 
high concentrations in the kidney, bladder, and liver, and the 
low permeation into other tissues. Population predictions 
of the quantified tissue concentrations are presented in the 
lower part of Fig. 3 and in the ESM. Metformin plasma, 
whole blood, kidney, and muscle concentrations are accu-
rately described by the model, governed by the implemented 
transport processes and the low passive permeability of 
metformin.
3.2  Impact of Organic Cation Transporter 2 
Polymorphism
The impact of the SLC22A2 808G>T single-nucleotide poly-
morphism on metformin exposure (DGI) was implemented 
using the same Michaelis–Menten constant for both isoforms 
[17, 20, 29], but an increased transport rate constant for each 
minor OCT2 allele (808T) present in the simulated popula-
tion. The 2.67-fold higher transport rate constant to describe 
the activity of the variant OCT2 (see metformin  drug-
dependent parameter table in the ESM) was optimized, 
based on the metformin plasma profiles of the homozygous 
808TT populations studied by Christensen et al. and Wang 
et al. [18, 21]. The metformin plasma concentrations of all 
other 808TT and 808GT study populations were predicted 
and are presented in Fig. 4. Except for one study reporting a 
higher metformin exposure with the variant OCT2 [29], the 
DGI AUC last ratios for the hetero- and homozygous groups 
are well predicted, with 6/7 within two-fold of the observed 
ratios (see the ESM).
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3.3  Drug–Drug Interaction Modeling 
with Cimetidine
In addition to the metformin model, a whole-body PBPK 
model of the potent MATE1 inhibitor cimetidine was 
developed. A detailed description of the cimetidine model 
development and evaluation is given in the ESM. The good 
model performance is demonstrated by population simula-
tions compared to observed data, a goodness-of-fit plot, and 
MRD values. Furthermore, predicted AUC last and Cmax val-
ues are documented, which are in good agreement with the 
observed data with GMFEs of 1.14 and 1.17, respectively.
The cimetidine-metformin DDI was modeled as competi-
tive inhibition of OCT1, OCT2, and MATE1 by cimetidine, 
using inhibition parameters from the literature [30]. How-
ever, cimetidine also is a BCS Class III drug (high solubility 
and low permeability) that is primarily excreted unchanged 
in the urine (renal clearance of approximately 400 mL/min 
[31]), indicating an important role of active transport in its 
distribution and excretion. As the only published informa-
tion on cimetidine kidney concentrations is a postmortem 
tissue-to-serum partition coefficient of 14.9 [32], which is 
not applicable for parameter optimization, the cimetidine 
interaction parameters were fixed to literature values and 
one of the cimetidine-metformin DDI studies [33] was uti-
lized to inform the intracellular kidney concentration in the 
cimetidine model parameter optimization. Population pre-
dictions of all clinical cimetidine-metformin DDI studies 
are presented in Fig. 5a–d. Predicted DDI AUC last and Cmax 
ratios are close to the observed values, with low GMFEs of 
1.22 and 1.20, respectively (see the ESM).
In the OCT2 polymorphism study by Wang et al. [21], the 
different SLC22A2 genotypes were additionally challenged 
with cimetidine co-administration, to show the combined 
effects of SLC22A2 808G>T DGI (decreased metformin 
plasma concentrations) and cimetidine DDI (increased 
metformin plasma concentrations). The predictions of this 












Fig. 1  Metformin transporters. Main sites of action of the transport-
ers that were implemented to model the absorption, distribution, 
and excretion of metformin. Several different studies report that they 
found no secretion of metformin to bile [2, 4, 7]. Drawings by Servier 
Medical Art, licensed under CC BY 3.0. MATE multidrug and toxin 
extrusion protein, OCT organic cation transporter, PMAT plasma 
membrane monoamine transporter
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f. Comparison of the metformin exposure of the three differ-
ent genotypes during cimetidine treatment (Fig. 5d–f, red tri-
angles) shows that the impact of the polymorphism becomes 
more pronounced with inhibition of MATE1. Quantitative 
evaluation of all DDI and DDGI predictions with plots of 
predicted vs observed AUC last and Cmax ratios are presented 
in the ESM.
3.4  Modeling of Renal Impairment
The impact of renal impairment on metformin pharma-
cokinetics was modeled by implementation of pathophysi-
ological changes for individuals with a GFR < 60 mL/min 
(CKD3A-CKD5). First, the actual individual GFR was used 
as reported. Second, renal secretion through OCT2 and 
MATE1 was decreased in proportion to the decrease in GFR, 
according to the “intact nephron hypothesis” [34–36]. Third, 
as metformin does not bind to plasma proteins, the levels of 
albumin and alpha-1-acid glycoprotein were not changed, 
but the hematocrit was gradually decreased with progressing 
stages of CKD [37]. As observed in previous PBPK analy-
ses of drug pharmacokinetics during renal impairment [36, 
38], these changes were not sufficient to describe the high 
metformin plasma concentrations in patients with CKD, 
suggesting the inhibition of further elimination pathways 
by uremic solutes that accumulate during renal impairment.
To incorporate this hypothesis by inhibition of basolateral 
OCT1 (liver uptake) and PMAT (skeletal muscle uptake), 
observed data of intravenously administered metformin in 
CKD3A-5 patients [6] were used to adjust the transport 
activities of OCT1 and PMAT for the different stages of 
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i    Metformin − 2550 mg po
Fig. 2  Metformin plasma concentrations. Population predictions 
of metformin plasma concentration–time profiles of representative 
intravenous (iv) and oral (po) studies, compared to observed data [2, 
4–6, 39, 52–54]. Population prediction arithmetic means are shown as 
lines; the shaded areas illustrate the 68% population prediction inter-
vals. Observed data are shown as dots (training dataset) or triangles 
(test dataset) ± standard deviation. Details on the study protocols, fur-
ther studies, and quantitative model performance measures are pro-
vided in the ESM. bid twice daily, qd once daily
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inhibition and GFR. This correlation was implemented and 
used to predict orally administered metformin in CKD. Fur-
thermore, to capture the broader shape of the metformin 
plasma concentration–time profiles in patients with CKD, 
the permeability at the basolateral side of the small intestinal 
mucosa cells was decreased. This permeability was already 
adjusted in the model for healthy individuals, to release the 
metformin from the enterocytes into the blood. Considering 
the negligible passive permeability of metformin, there are 
probably transporters involved at this membrane barrier as 
well, but because of the current lack of information on the 
identity of such transporters, the local passive permeability 
was adjusted in the model. Decreasing the basolateral small 
intestinal permeability in CKD might well be a surrogate 
for the inhibition of these unknown transporters by accu-
mulating uremic solutes, consistent with their inhibition of 
basolateral transporters of the liver.
Finally, although one would expect a progressive or even 
exponential increase of metformin plasma concentrations 
with decreasing kidney function, no apparent difference 
in the exposure of CKD3B and CKD4 patients could be 
observed in the available clinical data [12, 39], indicating 
adaptive processes in severe renal disease. Therefore, induc-
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a    Metformin - 1.445 µg iv b    Metformin - Blood c    Metformin - Kidney
d    Metformin - Liver e    Metformin - Intestines f    Metformin - Muscle
Fig. 3  Metformin tissue concentrations. Upper panel: pseudodynamic 
whole-body positron emission tomography imaging of a representa-
tive patient following an intravenous microdose of 11C-metformin [7] 
© SNMMI. a–f Population predictions of metformin blood and tissue 
concentration–time profiles measured in the 11C-metformin positron 
emission tomography study, compared to observed data [7]. Popula-
tion prediction arithmetic means are shown as lines; the shaded areas 
illustrate the 68% population prediction intervals. Observed data 
are shown as dots (training dataset) or triangles (test dataset). Lin-
ear plots are presented in the ESM. Bl bladder, He heart, iv intrave-
nous, K kidney, Liv liver, SG submandibular gland, SUV standardized 
uptake value = concentration [kBq/mL]·body weight [g]/injected dose 
[kBq]
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Fig. 4  Impact of organic cation 
transporter 2 (OCT2) polymor-
phism. Population predictions 
of metformin plasma concentra-
tion–time profiles in different 
SLC22A2 genotypes, compared 
to observed data [17, 18, 21, 
29]. Population prediction 
arithmetic means are shown as 
dark blue (SLC22A2 808GG, 
reference genotype) or lighter 
blue (SLC22A2 808GT and 
808TT, variant genotypes) lines. 
The shaded areas illustrate 
the respective 68% population 
prediction intervals. Observed 
data are shown as dots ± stand-
ard deviation. Details on the 
study protocols, semilogarith-
mic plots, and quantitative 
model performance measures 
are provided in the ESM. GG 
SLC22A2 808GG genotype, 
GT SLC22A2 808GT genotype, 
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 Wang 2008 − Metformin control − TT
Wang 2008 − with cimetidine − TT
n = 4
f    Metformin − 500 mg po
Fig. 5  Impact of drug–drug interaction (DDI) and drug–drug–gene 
interaction (DDGI). Population predictions of metformin plasma 
concentration–time profiles before and during cimetidine co-treat-
ment of different SLC22A2 genotypes, compared to observed data 
[21, 23, 33]. Population prediction arithmetic means are shown as 
solid blue (metformin only) or dashed red (DDI or DDGI) lines; the 
shaded areas illustrate the respective 68% population prediction inter-
vals. Observed data are shown as dots (metformin only) or triangles 
(DDI or DDGI) ± standard deviation. Details on the study protocols, 
semilogarithmic plots, and quantitative DDI and DDGI prediction 
performance measures are provided in the ESM. bid twice daily, GG 
SLC22A2 808GG genotype, GT SLC22A2 808GT genotype, po oral, 
qd once daily, qid four times daily, TT SLC22A2 808TT genotype
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rats [40], was assumed and incorporated for CKD4-5 
patients, greatly improving the predictions in severe renal 
disease (Fig. 6a, b). These changes in system-dependent 
parameters to model CKD3A-5 are summarized in Fig. 6 
(left table). The model performance for all available clini-
cal studies of metformin in renal disease is documented in 
the ESM.
The developed model of metformin in renal impairment 
was applied to generate dose recommendations for patients 
with CKD, that match the steady-state AUC of renally 
healthy individuals. Simulations of metformin plasma con-
centrations in CKD3A-5 patients compared to healthy vol-
unteers, all treated with 1000 mg of metformin three times 
daily, are shown in Fig. 6c. Simulations of metformin in 
patients with CKD administered with the model-based dose 
recommendations are shown in Fig. 6d. In the table below, 
these recommendations are compared to the guidance in 
the US and German labels. While the US label provides 
no quantitative advice [13], the German label recommends 
a reduction to 67% of the dose for CKD3A and to 33% for 
CKD3B patients [14]. Based on the scarce clinical data of 
metformin exposure in renally impaired patients, the pre-
sented model suggests much lower doses of about 30% for 
CKD3A and of 20% for CKD3B and 4.
4  Discussion
A comprehensive whole-body PBPK model of metformin 
has been thoroughly built and evaluated, integrating the cur-
rent knowledge on the mechanisms controlling the pharma-
cokinetics of this widely prescribed drug. The established 
model has been evaluated for prediction of the effects of 
the SLC22A2 808G>T polymorphism, the cimetidine-met-
formin DDI, and the impact of renal impairment, a frequent 
co-morbidity in patients with T2DM.
Several other PBPK models of metformin have been pub-
lished previously [41–44], but our newly developed model is 
the first to integrate PET-measured human in-vivo metformin 
kidney concentrations, clinical data of microdose studies, 
and a mechanistic description of the saturable transporter-
dependent absorption of metformin. The limitations of the 
presented model result from our lack of knowledge regarding 
the metformin pharmacokinetic processes in the liver and the 
expression levels of the different transporters throughout the 
body. As shown in Fig. 3d, the liver concentration–time pro-
file following the intravenous 11C-metformin microdose is 
not adequately described. The uptake of metformin into the 
liver is modeled via OCT1, but, in accordance with the lit-
erature, no process for metformin metabolism or secretion to 
bile has been implemented. An unspecific hepatic metabolic 
clearance was tested, but did not improve the model (causing 
underestimation of the plasma concentrations in studies with 
therapeutic doses), supporting the idea that metformin is not 
metabolized. The plasma concentrations following the oral 
11C-metformin microdose, and consequently also the meas-
ured tissue concentrations, are underpredicted for the 2 h 
of the oral PET study (see the ESM). However, the admin-
istered microdoses (1.445 µg intravenously and 0.856 µg 
orally) were more than 300,000 and 500,000 times below 
the lowest therapeutic dose of 500 mg. Given that the met-
formin pharmacokinetics are completely governed by satu-
rable transport processes and that the plasma, whole blood, 
kidney, and muscle concentrations following the intravenous 
microdose are well described, this underprediction might 
be caused by a missing process for metformin absorption.
The effect of the SLC22A2 808G>T polymorphism is 
difficult to assess from the literature. In-vitro studies report 
a decreased metformin transport rate [29], equal activity 
[20], as well as increased transport velocity [17] for the 
variant OCT2 protein. In-vivo, two studies report decreased 
clearance by renal secretion in Korean and Chinese 808TT 
individuals [21, 29], whereof the Chinese study neverthe-
less shows a non-significantly lower metformin plasma 
Cmax for the 808TT group. However, two different studies 
report increased clearance by renal secretion in American 
and European individuals [17, 18], with corresponding 
decreases in metformin exposure in association with the 
minor allele. Given that OCT2 and MATE1 are working 
sequentially to transport metformin through the kidney, it 
is difficult to distinguish their impacts on renal secretion. 
Therefore, statements regarding the effect of polymorphisms 
or co-medications on OCT2 function should not be based on 
plasma concentrations or renal secretion alone, without con-
comitant assessment of MATE1 genotype/activity or kidney 
concentrations. This also holds true for the DDGI results 
by Wang et al. [21] (Fig. 5f), where the observed lack of 
cimetidine-metformin DDI in SLC22A2 808TT individuals 
is difficult to explain, because (1) this DDI is mainly caused 
by inhibition of MATE1, (2) the MATE1 genotypes were 
not analyzed in this study, and (3) so far there are no in-vitro 
results available on the impact of cimetidine on MATE1 var-
iants. Another explanation for the weak effect of cimetidine 
in the SLC22A2 808TT group might be reduced transport of 
cimetidine by this OCT2 variant into the kidney and there-
fore less inhibition of MATE1, as previously proposed [30].
To model the renal impairment, renal secretion was 
decreased in proportion to the impaired GFR, based on the 
“intact nephron hypothesis”, which postulates that structur-
ally damaged nephrons stop contributing to both passive 
renal filtration and active secretion, and that the remaining 
intact nephrons continue to function in glomerulo-tubular 
balance with appropriate adaptation to the patient’s needs 
[35]. This hypothesis has been successfully applied in pre-
vious PBPK analyses of renal impairment [36, 42, 45, 46]. 
The inhibition of liver drug uptake by uremic toxins in renal 
1428 N. Hanke et al.
impairment has been postulated by Zhao et al. [38], based 
on the fact that the clearance of many nonrenally eliminated 
drugs is decreased in CKD, and based on their PBPK analy-
sis of repaglinide in CKD4.
We used an empirical approach to model the inhibition 
of liver and muscle uptake as a function of the degree of 
renal impairment. The inhibition of the basolateral intestinal 
permeability/transport in CKD is purely hypothetical, but 
was essential to describe the shape and elimination phase 
of the clinically observed data. The induction of OCT2 
and MATE1 was demonstrated in hyperuricemic rats [40]. 
To confirm and refine these hypotheses, in-vitro studies of 
a b
c d
Fig. 6  Impact of renal impairment and model-based chronic kidney 
disease (CKD) dose recommendations. a, b Population predictions 
of metformin plasma concentration–time profiles in different stages 
of CKD, compared to observed data [12, 39]. Population prediction 
arithmetic means are shown as black (healthy) or colored (CKD3A-4) 
lines. The shaded areas illustrate the respective 68% population pre-
diction intervals. Observed data are shown as dots in corresponding 
colors. c Simulations of metformin exposure in CKD3A-5 patients 
compared to healthy individuals using an oral (po) dose of 1000 mg, 
three times daily (tid). d Simulations of metformin exposure in 
CKD3A-5 patients to match the steady-state area under the curve 
(AUC) of 1000  mg po, tid in healthy individuals. The tables show 
the implementation of renal impairment (on the left) and the model-
based dose recommendations compared to the guidance in the US and 
German labels (on the right). contraind. contraindicated, GFR glo-
merular filtration rate, HKT hematocrit, intest. perm. intestinal per-
meability, MATE multidrug and toxin extrusion protein, OCT organic 
cation transporter, PMAT plasma membrane monoamine transporter
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OCT1 and PMAT inhibition by uremic solutes are needed, 
to identify the toxins involved and to assess their inhibitory 
potential; the expression and role of transporters at the baso-
lateral membrane of the intestinal mucosa has to be inves-
tigated; and the clinical relevance of OCT2 and MATE1 
induction by uric acid in humans needs to be established.
Future applications include the modeling of further DGIs 
and DDIs, and ultimately, the individualized dose recom-
mendation for real patients with multiple polymorphisms, 
co-medications, and co-morbidities. Although the effects 
of some of these interactions do not reach statistical sig-
nificance in the blood, their impact on kidney or liver con-
centrations might well be substantial and of therapeutic 
relevance. The model application with the most immediate 
medical benefit is the generation of dose recommendations 
for renally impaired patients with T2DM. Chronic kid-
ney disease is a frequent co-morbidity, but physicians are 
reluctant to prescribe metformin to patients with reduced 
renal function because of the contraindication given in most 
guidelines and fear of lactic acidosis caused by metformin 
accumulation [47]. These contraindications are based solely 
on the estimated GFR of the patient, even though for patients 
with stable renal disease, a dose adjustment based on renal 
function, with monitoring of the metformin plasma con-
centrations, would be perfectly feasible. A reduced dose of 
500 mg metformin daily was reported to be safe for creati-
nine clearances as low as 20 mL/min [48] and in a group 
of CKD4 patients [12], which is in line with the presented 
model-based recommendation of 200 mg three times daily 
for CKD4 patients with T2DM.
5  Conclusions
Mechanistic whole-body PBPK models of metformin and 
cimetidine have been carefully developed and evaluated to 
integrate the current pharmacokinetic knowledge on these 
drugs and to describe the impact of the SLC22A2 808G>T 
polymorphism, the cimetidine-metformin DDI, and the 
pathophysiological changes during renal impairment on the 
exposure of metformin. Both models will be released open-
source (https ://www.open-syste ms-pharm acolo gy.org) [49], 
to support metformin therapy, OCT2/MATE DDI studies 
during drug development, and to be used as input for phar-
macodynamic glucose-homeostasis models [50, 51] and 
other PBPK/pharmacodynamic analyses. The presented 
analysis has generated insights into the pharmacokinet-
ics during renal impairment, indicating that the kidneys of 
patients with severe renal disease might be able to adapt to 
uremia/hyperuricemia by induction of OCT2 and MATE1, 
as has been shown for hyperuricemic rats [40].
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